IMNMImmunome, Inc.Running, no new patients
A Study of AL102 in Patients With Progressing Desmoid Tumors
Desmoid · Desmoid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 198 (final count)
- Started
- Sep 1, 2021
- Main results expected
- Dec 3, 2025
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Safety and Tolerability - Adverse Events
Measured over: Approximately 1.5 years
Part B: Progression free survival (PFS)
Measured over: Approximately 2 years
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT04871282 · record last updated 2026-06-08 · checked 2026-11-09 15:47 UTC